Skip to main content

Krystal Biotech Inc (KRYS) Stock

Krystal Biotech Inc Stock Details, Movements and Public Alerts

Stock Details

Krystal Biotech Inc (KRYS), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $268.54. Over the past 52 weeks, it has ranged between $122.80 and $298.30. This places the current price at 90.0% of its 52-week high and 118.7% above its 52-week low. Recent trading volume was recorded at 246,232. The 14-day Relative Strength Index (RSI) stands at 43.77, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $269.80 by 0.47%. Similarly, it is above its 200-day moving average of $199.95 by 34.30%. The MACD histogram is -0.51, indicating bearish momentum (MACD Line: -4.57, Signal Line: -4.06).

52-Week Range

$298.30 - $122.80

-9.98% from high · +118.68% from low

Avg Daily Volume

270,973

20-day average

100-day avg: 306,233

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

37.87

Above market average

Forward P/E

44.84

Earnings expected to decline

Price to Book

6.25

EV/EBITDA

40.55

EPS (TTM)

$6.84

Price to Sales

19.59

Beta

0.54

Less volatile than market

Q:How is KRYS valued relative to its earnings and growth?
Krystal Biotech Inc trades at a P/E ratio of 37.87, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 44.84 is higher than the current P/E, indicating analysts expect earnings to decline over the next year.
Q:What is KRYS's risk profile compared to the market?
With a beta of 0.54, Krystal Biotech Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.25 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

52.60%

Operating Margin

41.30%

EBITDA

$162.92M

Return on Equity

18.90%

Return on Assets

8.44%

Revenue Growth (YoY)

17.50%

Earnings Growth (YoY)

11.60%

Q:How profitable and efficient is KRYS's business model?
Krystal Biotech Inc achieves a profit margin of 52.60%, meaning it retains $52.60 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 41.30% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 18.90% and ROA at 8.44%, the company generates strong returns on invested capital.
Q:What are KRYS's recent growth trends?
Krystal Biotech Inc's revenue grew by 17.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 11.60% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$7.6B

Revenue (TTM)

$389.13M

Revenue/Share (TTM)

$13.44

Shares Outstanding

29.44M

Book Value/Share

$41.78

Asset Type

Common Stock

Q:What is KRYS's market capitalization and position?
Krystal Biotech Inc has a market capitalization of $7.6B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 29.44M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does KRYS's price compare to its book value?
Krystal Biotech Inc's book value per share is $41.78, while the current stock price is $268.54, resulting in a price-to-book (P/B) ratio of 6.43. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$314.00

16.93% upside potential

Analyst Recommendations

Strong Buy

0

Buy

10

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for KRYS?
11 analysts cover KRYS with 91% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $314.00 implies 16.9% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on KRYS?
Current analyst recommendations:010 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Apr 12, 2026, 02:48 AM

Technical Indicators

RSI (14-day)

43.77

Neutral

50-Day Moving Average

$269.80

-0.47% below MA-50

200-Day Moving Average

$199.95

34.30% above MA-200

MACD Line

-4.57

MACD Signal

-4.06

MACD Histogram

-0.51

Bearish

Q:What does KRYS's RSI value tell investors?
The RSI (Relative Strength Index) for KRYS is currently 43.77, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret KRYS's MACD and moving average crossovers?
MACD analysis shows the MACD line at -4.57 below the signal line at -4.06, with histogram at -0.51. This bearish crossover indicates downward pressure. The 50-day MA ($269.80) is above the 200-day MA ($199.95), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 21, 2026, 12:59 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for KRYS and get notified when the price changes.

Stay Ahead of the Market with Krystal Biotech Inc Alerts

Set up price alerts for Krystal Biotech Inc and get notified instantly when the price hits your target. Never miss an important price movement again.